Xalaprost 5ML


Xalaprost 5ML


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)






Patients with open-angle glaucoma or ocular hypertension should use Latanoprost Sterile Ophthalmic Solution to lower their intraocular pressure.



Latanoprost is a prostaglandin F2 analogue. Latanoprost is a prostanoid-specific FP receptor agonist thought to lower intraocular pressure (IOP) via enhancing aqueous humor outflow. Increased uveoscleral outflow appears to be the major mechanism of action in both animals and humans. Glaucomatous field loss is linked to an increase in intraocular pressure (IOP). The higher the IOP, the more likely it is that the optic nerve will be damaged and the vision field will be lost.


Dosage & Administration

The recommended dosage is 1 drop (1.5 mcg) in the affected eye(s) once daily in the evening. This is for topical ophthalmic use only. Not for injection or oral use.



When thimerosal-containing eye drops are combined with latanoprost, in vitro tests demonstrate that precipitation occurs. If such medicines are utilized, they should be given with at least a 5-minute gap between administrations.



Hypersensitivity to latanoprost, benzalkonium chloride, or any of the other components in this medication is known.


Side Effect

Changes in eyelashes (increased length, thickness, pigmentation, and number of eyelashes); darkening of the eyelid skin; intraocular inflammation (iritis/uveitis); changes in iris pigmentation; and macular edema, including cystoid macular edema. In a 6-month active control, double-sided mask, and multicenter trial, 5-15% of patients treated with latanoprost reported adverse ocular reactions and ocular signs and symptoms as blurred vision, burning and tingling, Conjunctival hyperemia, foreign body sensation, itching, increase skin pigmentation. Iris and punctate epithelial keratopathy. Local conjunctival hyperemia was observed; however, less than 1% of patients treated with latanoprost required discontinuation of treatment due to intolerance to conjunctival hyperemia.


Pregnancy & Lactation

Pregnancy Classification C. In pregnant women, there are no appropriate and well-controlled trials. Only if the possible benefit outweighs the danger to the fetus should the medication be taken during pregnancy.


Precautions & Warnings

Eye drops can gradually increase the pigmentation of the iris. The change in eye color is due to increased melanin content in the stromal melanocytes of the iris, not to the increased number of melanocytes. During clinical trials, the increase in iris brown pigment did not appear to develop further after stopping treatment, but the resulting color change may be permanent. Darkening of the skin of the eyelids, which may be reversible. It can increase the length, thickness, pigmentation, number of eyelashes or hair and incorrect growth of the eyelashes. Eyelash changes are usually reversible after stopping treatment. Patients with a history of intraocular inflammation (iritis / uveitis) should be used with caution and, in general, should not be used in patients with active intraocular inflammation. For patients without an intact posterior capsule or known risk factors for macular edema, the drug should be used with caution.


Therapeutic Class

Drugs for miotics and glaucoma


Storage Conditions

Before opening the cap, keep the bottle in its box in a refrigerator (2°-8° C) protected from light. After opening, keep the bottle in its box in a cool place below 25° C. The contents should be used within one month after the dropper is opened. Keep out of reach of children


Pharmaceutical Name

Beximco Pharmaceuticals Ltd.